{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:19:49Z","timestamp":1792037989989,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.semcancer.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T11:52:10Z","timestamp":1684929130000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Advancements in small cell lung cancer"],"prefix":"10.1016","volume":"93","author":[{"given":"Jung-hoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semcancer.2023.05.008_bib1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses, and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.semcancer.2023.05.008_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2023.05.008_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","article-title":"Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer","volume":"1","author":"Stewart","year":"2020","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2023.05.008_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.semcancer.2023.05.008_bib5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.semcancer.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.semcancer.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.21037\/jtd.2018.07.120","article-title":"Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer","volume":"10","author":"Boumber","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.semcancer.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","article-title":"Molecular profiles of small cell lung cancer subtypes: therapeutic implications","volume":"20","author":"Schwendenwein","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"13\u201314","key":"10.1016\/j.semcancer.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gad.314815.118","article-title":"POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer","volume":"32","author":"Huang","year":"2018","journal-title":"Genes Dev."},{"issue":"23","key":"10.1016\/j.semcancer.2023.05.008_bib12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.05.008_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.05.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.semcancer.2023.05.008_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032","volume":"14","author":"Ready","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2023.05.008_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.05.008_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.semcancer.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7563","key":"10.1016\/j.semcancer.2023.05.008_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2023.05.008_bib24","article-title":"A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC","volume":"35","author":"Pawel","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2023.05.008_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8514","article-title":"Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer","volume":"37","author":"Park","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2023.05.008_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.5562","article-title":"A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors","volume":"34","author":"Hamilton","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.05.008_bib27","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/j.jtho.2016.11.253","article-title":"Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer","volume":"12","author":"Owonikoko","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.05.008_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","article-title":"Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies","volume":"22","author":"Weiss","year":"2021","journal-title":"Clin. Lung Cancer"},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2023.05.008_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8530","article-title":"Phase 1\/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results","volume":"35","author":"Atrafi","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2023.05.008_bib30","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.05.008_bib31","doi-asserted-by":"crossref","first-page":"P1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II study.","volume":"14","author":"Thomas","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.05.008_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2023.05.008_bib34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2023.05.008_bib35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2023.05.008_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2017.11.018","article-title":"Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer","volume":"115","author":"Tanaka","year":"2018","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2023.05.008_bib38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2023.05.008_bib39","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study","volume":"16","author":"Johnson","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"23","key":"10.1016\/j.semcancer.2023.05.008_bib40","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed\/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.semcancer.2023.05.008_bib41","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.05.008_bib42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2023.05.008_bib43","doi-asserted-by":"crossref","unstructured":"Hossein Borghaei, M..B, M. Johnson, AMG 757, a half-life extended bispecific T-cell engager (BiTE\u00ae) immune therapy against DLL3 in SCLC: phase 1 interim results. 2020, Society for Immunotherapy of Cancer Virtual Congress 2020.","DOI":"10.1136\/jitc-2020-SITC2020.0359"},{"issue":"10","key":"10.1016\/j.semcancer.2023.05.008_bib44","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1016\/j.jtho.2018.08.1826","article-title":"Targeting DLL3 with AMG 757, a BiTE\u00ae Antibody Construct, and AMG 119, a CAR-T, for the treatment of SCLC.","volume":"13","author":"Giffin","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2023.05.008_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8576","article-title":"Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed\/refractory small cell lung cancer (SCLC)","volume":"37","author":"Byers","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.05.008_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.semcancer.2023.05.008_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gronberg","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9962","key":"10.1016\/j.semcancer.2023.05.008_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2023.05.008_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2017.03.007","article-title":"Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial","volume":"108","author":"Slotman","year":"2017","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2023.05.008_bib50","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.05.008_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12885-018-5251-3","article-title":"Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis","volume":"19","author":"Yin","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2023.05.008_bib52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.05.008_bib53","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.21037\/jtd.2020.03.80","article-title":"Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer","volume":"12","author":"Taylor","year":"2020","journal-title":"J. Thorac. Dis."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:12:05Z","timestamp":1760919125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X23000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":49,"alternative-id":["S1044579X23000822"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.008","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}